BEYFORTUS^®
(nirsevimab)
SANOFI
HK Reg. No. HK-68490, HK-68491 (13 Dec, 2024)
Composition:²

• Beyfortus 100 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 100 mg of nirsevimab in 1 mL (100 mg/mL)

• Beyfortus 50 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 50 mg of nirsevimab in 0.5 mL (100 mg/mL)

Indication:²

• Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season

References

1. Therapeutic Goods Administration, Australia. Product Information. 18 March 2024. Available from:  https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2022-PI-01599-1&d=20250103172310101. [Accessed 3 January 2025]. 2. European Medicines Agency. Summary of Product Characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2023/20231201161202/anx_161202_en.pdf. [Accessed 3 January 2025].  3. EMC. Quofenix 300 mg powder for concentrate for solution for infusion SmPC. Available from: https://www.medicines.org.uk/emc/product/11481/smpc#about-medicine. [Accessed 3 January 2025].  4. European Medicines Agency. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. [Accessed 3 January 2025].